论文部分内容阅读
Aim: The aim of the present study was to investigate the relationship between R219K, M883I, and R1587K variants of the ATP-binding cassette transporter sub-family A number 1 (ABCA1) gene and response to rosiglitazone treatment in newly diagnosed patients with type 2 diabetes. Methods: A total of 105 diabetic patients with no history of antihyperglycemia medication were treated with rosiglitazone (4 or 8 mg daily) for48 weeks. Three non-synonymous variants R219K, M8831, and R 1587K, were genotyped in all patients. Results: Ninety-three patients com-pleted the entire study. The R219K variant of ABCA1 had an effect on rosiglitazone response with the per-allele odds ratio of 2.04 for treatment failure (P<0.05). The RR homozygotes had a better improvement in indicators of insulin sensitivity, as determined by a significantly greater decrease in the homeostasis model assess-ment index of insulin resistance (-2.39±0.46 vs-0.69±0.51, P<0.05). No genotype-phenotype association was detected for M883I and R1587K. Conclusion: The R219K variant of ABCA1 was associated with the therapeutic effect of rosiglitazone. The RR homozygotes had a better response to rosiglitazone treatment in terms of insulin ,sensitivity improvement than minor K allele carders. Neither the M883I nor R1587K variant of the ABCA1 gene was associated with rosiglitazone response.